levamlodipine: used to treat angina and hypertension; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(S)-amlodipine : The (4S)-enantiomer of amlodipine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9822750 |
| CHEMBL ID | 2111097 |
| CHEBI ID | 53796 |
| SCHEMBL ID | 41283 |
| MeSH ID | M0537995 |
| Synonym |
|---|
| 103129-82-4 |
| CHEBI:53796 , |
| (s)-amlodipine |
| 3-ethyl 5-methyl (4s)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| A800681 |
| S3674 |
| BCP9000849 |
| (-)-amlodipine |
| levoamlodipine |
| (4s)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester |
| 3-ethyl 5-methyl (4s)-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| 0p6nlp6806 , |
| s-amlodipine |
| 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4s)- |
| levamlodipine |
| levamlodipine [inn] |
| unii-0p6nlp6806 |
| 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine |
| AKOS015896087 |
| 3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4s)- |
| AM90308 |
| SCHEMBL41283 |
| agsav301 component levamlodipine |
| amlodipine, (s)- |
| levamlodipine [who-dd] |
| CHEMBL2111097 |
| Q-101935 |
| DB09237 |
| HTIQEAQVCYTUBX-KRWDZBQOSA-N |
| BCP22052 |
| DTXSID50904504 |
| 3-ethyl 5-methyl (s)-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| HY-14744 |
| Q6534831 |
| CS-0003533 |
| HMS3885M19 |
| mfcd09832686 |
| CCG-268748 |
| 3-o-ethyl 5-o-methyl (4s)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate |
| D97381 |
| BS-42190 |
| EN300-19633977 |
| s-amlodipine besylate |
| levamlodipino |
| levamlodipinum |
Levamlodipine (LEE) is a drug commonly used for antihypertensive treatment in clinical therapy.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Levamlodipine (LEE) is a drug commonly used for antihypertensive treatment in clinical therapy. " | ( Investigation of the binding properties between levamlodipine and HSA based on MCR-ALS and computer modeling. Huang, X; Jiang, Z; Liu, Z; Tuo, X, 2021) | 2.32 |
Study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | ( Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) | 0.91 |
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | ( Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) | 1.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times can effectively treat NDH, but bedtime dosing is more beneficial in reducing nocturnal blood pressure, reversing NDH, improving the circadian rhythm of blood pressure, left ventricular structure, regulating vascular endothelial function, increasing MMPs levels, and reducing TIMP levels." | ( Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) | 1.38 |
| Class | Description |
|---|---|
| amlodipine | A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (35.71%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (64.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||